|
⚲
|
| Keyboard |
| Oracle Investment Management Inc
✚
|
|
|---|---|
| CRD # | 138127 |
| SEC # | 801-73596 |
| CIK # | 0001012622, 0001341439 |
| AUM | |
| Employees | 4 (75% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 203-862-7900 |
| Address | 177 W Putnam Avenue Greenwich, CT 06902 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (4/3/2023) [Brochure] |
|---|
Item 5 Fees and Compensation
As investment adviser to the Funds, Oracle receives a management fee in accordance with each Fund’s
confidential private offering memorandum, which is generally based on assets under management. Below is a
summary of the fee structure for each of the funds currently managed by Oracle:
OP & OIP: Oracle receives a management fee at an annual rate of up to 1.5% - 2% of the value of the
net assets of the Funds, as of the first business day of each fiscal quarter. The management fee is
payable in advance, as of the first day of each fiscal quarter. Management fees, with respect to
contributions made on a day other than the first day of a fiscal quarter, will be pro-rated. Management
fees, with respect to redemptions made on a day other than the last day of a fiscal quarter, will be
returned for payment or credited to the redeeming Investor.
TEN: Oracle receives a management fee at an annual rate of up to 1.5% - 2% of the month-end capital
account balance of each Limited Partner. This fee, payable quarterly in arrears, is charged to each
Limited Partner’s Capital balance, as of the first day of the following month.
The Funds pay these fees by debiting the accounts of investors in each given Fund, as applicable. Investors do
not have the option to be billed directly for the fees incurred. Management fees are generally not negotiable;
however, Oracle maintains the right to waive or modify the management fees for investors of the Fund that are
the Principals, members, employees or affiliates of Oracle (or General Partner, as applicable), members of the
immediate families of such persons, and for certain large or strategic investors.
Item 4 Advisory Business Page 3 of 14
Oracle Investment Management, Inc. | Form ADV Part 2A Brochure| March 2023 Back to Table of Contents
The Funds pay for organizational and initial offering expenses as well as ongoing operating expenses, including
but not limited to accounting, auditing, bank fees, tax preparation, legal, administration, research, and trading
costs. The Funds also incur brokerage and other transaction costs. For further detail, including Soft Dollar use,
within and outside of Section 28E of the Securities Act of 1934, please refer to the Soft Dollar detail Item 12:
Brokerage Practices (pg 11) of this Brochure.
Expenses incurred for the benefit of one or more Clients are generally allocated pro-rata in proportion to the
relative net asset value of each of such Clients or any other manner Oracle determines to be fair and reasonable
in light of the circumstances, taking account of what is practicable.
Oracle and its employees do not accept compensation, including sales charges or service fees, from any person
for the sale of securities or other investment products. |
| Account Minimums and Types of Clients — Form ADV Part 2A (4/3/2023) [Brochure] |
|---|
Item 7 Types of Clients
The Firm’s Clients are the Funds. Investors in the Funds consist primarily of institutional investors, high net
worth individuals, and family offices.
The minimum initial investment for each Fund is as follows:
Oracle Partners, L.P. US $ 2 million
Oracle Institutional Partners, L.P. US $ 1 million
Oracle Ten Fund, L.P. US $ 1 million
Item 6 Performance-Based Fees & Side-By-Side Management Page 4 of 14
Oracle Investment Management, Inc. | Form ADV Part 2A Brochure| March 2023 Back to Table of Contents |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| CM Life Sciences Inc | 0.1 | ||
| Ardelyx Inc | 0.0 | ||
| Biohaven Ltd | 0.0 | ||
| Quidelortho Corp | 0.0 | ||
| Personalis Inc | 0.0 | ||
| Teladoc Inc | 0.0 | ||
| Taysha Gene Therapies Inc | 0.0 | ||
| CAVA Group Inc | 0.0 | ||
| Edgewise Therapeutics Inc | 0.0 | ||
| Biogen IDEC Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Oracle Ten Fund LP | 2019-03-29 | 16.7 M | |
| HF | Oracle Institutional Partners LP | 2012-02-14 | 18.4 M | |
| HF | Oracle Offshore Limited | 2012-02-14 | 11.4 M | |
| HF | Oracle Partners LP | 2012-02-14 | 174.1 M | |
| HF | Oracle Ten Fund Master LP | 2012-02-14 | 137.0 M |
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 3 | 209.1 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 3 | 209.1 |
| By Discretionary | ||
| Discretionary | 3 | 209.1 |
| Non-Discretionary | 0 | 0.0 |
| Total | 3 | 209.1 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 209.1 | |
| Total | 3 | 209.1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001012622] | |
| 3 | [0001012622] | |
| 4 | [0001012622] | |
| 10-K | [0001341439] | |
| 10-Q | [0001341439] | |
| 3 | [0001341439] | |
| 4 | [0001341439] | |
| 8-K | [0001341439] | |
| SC 13D | [0001341439] | |
| SC 13G | [0001341439] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 254900MY3GRHAO1BKI91 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Oracle Corp | |
| Henley Jeffrey | |
| Boskin Michael J | |
| Mihaljevic Tomislav | |
| Fairhead Rona Alison | |
| Chizen Bruce R | |
| Berg Jeffrey | |
| Ablo Awo | |
| Rusckowski Stephen H | |
| Moorman Charles W | |
| View All | |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Oracle Corp ORCL
Common Stock
|
2026-02-09 | Sell | 10,000 | $155.23 | 1,552,300 |
|
Oracle Corp ORCL
Restricted Stock Unit · derivative
|
2026-01-23 | Grant | 337.78 | $177.16 | 59,841 |
|
Oracle Corp ORCL
Common Stock
|
2026-01-15 | Sell | 35,000 | $194.89 | 6,821,150 |
|
Oracle Corp ORCL
Common Stock
|
2025-12-24 | Sell | 15,000 | $196.89 | 2,953,350 |
|
Oracle Corp ORCL
Common Stock
|
2025-12-23 | Other | 199,071 | $0.00 | |
|
Oracle Corp ORCL
Common Stock
|
2025-12-23 | Sell | 2,223 | $196.61 | 437,064 |
|
Oracle Corp ORCL
Common Stock
|
2025-12-22 | Gift | 5,000 | $0.00 | |
|
Oracle Corp ORCL
Common Stock
|
2025-12-19 | Sell | 10,000 | $192.52 | 1,925,200 |
|
Oracle Corp ORCL
Common Stock
|
2025-12-05 | Tax withheld | 5,740 | $214.33 | 1,230,254 |
|
Oracle Corp ORCL
Common Stock
|
2025-12-05 | Option exercise | 11,016 | $0.00 | |
|
Oracle Corp ORCL
Restricted Stock Unit · derivative
|
2025-12-05 | Option exercise | 11,016 | $0.00 | |
|
Oracle Corp ORCL
Restricted Stock Unit · derivative
|
2025-11-18 | Grant | 793 | $0.00 | |
|
Oracle Corp ORCL
Common Stock
|
2025-10-28 | Sell | 4,226 | $284.31 | 1,201,494 |
|
Oracle Corp ORCL
Common Stock
|
2025-10-28 | Sell | 13,373 | $282.56 | 3,778,675 |
|
Oracle Corp ORCL
Common Stock
|
2025-10-28 | Sell | 9,042 | $281.58 | 2,546,046 |
|
Oracle Corp ORCL
Common Stock
|
2025-10-28 | Sell | 22,724 | $283.63 | 6,445,208 |
|
Oracle Corp ORCL
Restricted Stock Unit · derivative
|
2025-10-23 | Grant | 142.94 | $280.07 | 40,033 |
|
Oracle Corp ORCL
Stock Option · derivative
|
2025-10-23 | Grant | 428,465 | $0.00 | |
|
Oracle Corp ORCL
Restricted Stock Unit · derivative
|
2025-10-23 | Grant | 35,706 | $0.00 | |
|
Oracle Corp ORCL
Restricted Stock Unit · derivative
|
2025-10-23 | Grant | 32,135 | $0.00 | |
| showing 20 of 200 most recent transactions | |||||